Anavex Life Sciences Corp. Stock News

ANAVEX®3-71 effect is supported by biomarkers: Decrease of extracellular A (Abeta) deposition and reduced pathological inflammatory glial cell recruitment towards hippocampal neurons (p ≤ 0.01) ANA

Expression levels of pathological dysregulated neurodegenerative genes of both Alzheimer’s and Parkinson’s disease were significantly restored by the therapeutic effect of ANAVEX®2-73 (p<0.005)

Gainers AMTD Digital Inc. (NYSE: HKD) climbed 71.5% to close at $27.80 on Monday after gaining 108% on Friday. The company priced its IPO at $7 per share. SKYX Platforms Corp. (NASDAQ: SKYX) jumped

The average of price targets set by Wall Street analysts indicates a potential upside of 179.5% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionab

The average of price targets set by Wall Street analysts indicates a potential upside of 179.5% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionab

Endo International (ENDO) tanks 26%, cooling off after its massive stock price surge on Tuesday, post the Supreme Court's decision to overturn Roe v. Wade.

Global Blood Therapeutics (GBT) initiates the phase II portion of its planned phase II/III studies on pipeline candidate GBT601 to identify the optimal dose for the pivotal phase III portion of the tr

BioMarin (BMRN) receives a positive CHMP opinion for Roctavian, its gene therapy for treating adults with hemophilia A. The European Commission's decision is expected by the third quarter of 2022.

The average of price targets set by Wall Street analysts indicates a potential upside of 238.3% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionab

The average of price targets set by Wall Street analysts indicates a potential upside of 238.3% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionab

Celldex (CLDX) initiates dosing in a mid-stage study designed to evaluate its antibody candidate, barzolvolimab, for treating patients with chronic spontaneous urticaria.

The FDA approves label expansion of Rhythm Pharma's (RYTM) Imcivree to include Bardet-Biedl Syndrome patients. However, the FDA provides CRL for label expansion of the drug in Alstrom syndrome.

The average of price targets set by Wall Street analysts indicates a potential upside of 286.4% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionab

Short-term catalysts may have some effect on Cassava Sciences' stock value but the key to the company's success (or failure) are results from two phase three clinical trials.

Immunovant's (IMVT) earnings miss estimates in fiscal fourth quarter ended on Mar 31, 2022. The company achieves FDA alignment for phase III study on batoclimab in thyroid eye disease.